RAB17 and breast cancer: Consistent with our previous results, we found that low levels of Rab17 expression in breast tumours was strongly associated with poor overall patient survival (P<0.0001) (Fig. 1A), and this was statistically significant in all breast cancer intrinsic subtypes (Fig. S1A–C), with the exception of the HER-enriched subtype (Fig. S1D).